source
- Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugA deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.BioPharma Dive · 2mo ago↗ source
- Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionThe wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.BioPharma Dive · 2mo ago↗ source
- A year after Vertex’s big launch, pain drug research faces a pivotal momentJournavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?